Showing results (1821-1830 of 1,896) with videos related to

Sort By:
Pageof 190
Blood|November 1, 2021
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamideEphraim J Fuchs, Shannon R McCurdy, Scott R Solomon, et al.
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
The Journal of Rheumatology|October 16, 2020
Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus ErythematosusDaniela Dominguez, Sylvia Kamphuis, Joseph Beyene, et al.
Experimental Neurology|October 7, 2014
Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff diseaseAllison M Bradbury, Heather L Gray-Edwards, Jamie L Shirley, et al.
Journal of the Canadian Association of Gastroenterology|August 5, 2026
Nationalization of clinical care pathways for inflammatory bowel disease management in CanadaKaitlyn Delaney Chappell, Aalia Tausif, Cynthia H Seow, et al.
Annals of the Rheumatic Diseases|August 17, 2022
Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosusLingxiao Xu, Jian Zhao, Qing Sun, et al.
European Journal of Pharmacology|July 28, 2024
The Mitragyna speciosa (kratom) alkaloid mitragynine: Analysis of adrenergic α2 receptor activity in vitro and in vivoSamuel Obeng, Morgan L Crowley, Marco Mottinelli, et al.
Cancer Cell|July 16, 2021
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activityJoel D Pearson, Katherine Huang, Marek Pacal, et al.
Gastro Hep Advances|January 26, 2026
Rates and Factors Associated With Hepatocellular Carcinoma Diagnosis, Stage, Treatment, and SurvivalGeorge N Ioannou, Vera Yakovchenko, Tamar Taddei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE StudyDavid A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.
Pageof 190